|
PicksThatMove: www.PicksThatMove.com: www.PicksThatMove.com: www.PicksThatMove.com Alerts, June 30, 2009: IDTI, TASR, GERN, FFIV, VIRL and VICL.
Jun 30, 2009 (M2 PRESSWIRE via COMTEX) --
Picksthatmove.com Alerts include Integrated Device Technology, Inc. (NASDAQ: IDTI); TASER International, Inc. (Nasdaq: TASR); Geron Corporation (Nasdaq: GERN); F5 Networks, Inc. (NASDAQ: FFIV); Virage Logic Corporation (NASDAQ: VIRL) and Vical Incorporated (Nasdaq: VICL)
-- Jun 29, 2009 Integrated Device Technology, Inc. (NASDAQ:IDTI) closed at $6.00 on a volume of 2,743,724 shares.
IDT Introduces New Family of VersaClock(TM) Timing Devices
New Timing Devices Offer Greater Flexibility and Improved Performance for Designers of High-Performance Consumer, Telecommunications, Networking and Data Communications Applications
SAN JOSE, Calif., Jun 30, 2009 -- IDT(R) (Integrated Device Technology, Inc.)(NASDAQ:IDTI), a leading provider of essential mixed signal semiconductor solutions that enrich the digital media experience, today announced the newest members of its VersaClock(TM) family of timing devices. VersaClock III devices are programmable clock generators specifically designed for use in high-performance consumer, telecommunications, networking and data communications applications and are more versatile alternatives to using multiple crystals and oscillators. These programmable timing solutions are critical in reducing board space and maintaining power efficiency where volumes may not allow full custom solutions. Multiple systems, with widely varying requirements, can consolidate to fewer of these programmable devices improving inventory management.
About IDT
With the goal of continuously improving the digital media experience, IDT integrates its fundamental semiconductor heritage with essential innovation, developing and delivering low-power, mixed signal solutions that solve customer problems. Headquartered in San Jose, Calif., IDT has design, manufacturing and sales facilities throughout the world. IDT stock is traded on the NASDAQ Global Select Stock Market(R) under the symbol "IDTI." Additional information about IDT is accessible at www.IDT.com.
-- Jun 29, 2009 TASER International, Inc. (Nasdaq:TASR) closed at $4.55 on a volume of 794,373 shares.
TASER XREP Ready to Fly
Wireless TASER Round Achieves Groundbreaking 100 Foot Range, Available Now
SCOTTSDALE, Ariz., Jun 30, 2009 -- TASER International, Inc. (Nasdaq:TASR), a leading provider of technology solutions and the market leader in electronic control devices (ECDs), announces that the long awaited self-contained wireless TASER(r) eXtended Range Electronic Projectile (XREP(tm)) shotgun rounds are now available. Together with O.F. Mossberg & Sons, Inc. a leader in the design and manufacturing of firearms, we further announce the commercial launch of the TASER(r) X12(tm) Less-Lethal Shotgun (LLS) by Mossberg(r).
About TASER International, Inc.
TASER International's products protect life. TASER provides advanced Electronic Control Devices (ECDs) for use in the law enforcement, medical, military, corrections, professional security, and personal protection markets. TASER devices use proprietary technology to incapacitate dangerous, combative, or high-risk subjects who pose a risk to law enforcement officers, innocent citizens, or themselves in a manner that is generally recognized as a safer alternative to other uses of force. For more information, please call TASER International at (800) 978-2737 or visit our website at www.TASER.com.
-- Jun 29, 2009 Geron Corporation (Nasdaq:GERN) closed at $6.69 on a volume of 913,341 shares.
GE Healthcare and Geron Announce Exclusive Global Agreement to Commercialize Stem Cell Drug Discovery Technologies
CHALFONT ST GILES, England & MENLO PARK, Calif., Jun 30, 2009 -- GE Healthcare, a unit of General Electric Company (NYSE:GE), and Geron Corporation (Nasdaq:GERN) today announced that they have entered into a global exclusive license and alliance agreement to develop and commercialize cellular assay products derived from human embryonic stem cells (hESCs) for use in drug discovery, development and toxicity screening. The program will use stem cells derived from hESC lines listed on the NIH Human Pluripotent Stem Cell Registry. Financial terms are not being disclosed.
About Geron
Geron is a biopharmaceutical company that is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The products are based on our core expertise in telomerase and human embryonic stem cells. For more information about Geron, visit www.geron.com.
-- Jun 29, 2009 F5 Networks, Inc. (NASDAQ: FFIV) closed at $34.95 on a volume of 1,566,435 shares.
F5 BIG-IP Solutions Integrated with VMware vCenter(TM) Server to Support More Rapid Alignment of IT to Business Requirements
Tightly Integrated Solution Affords Enterprises a More Agile IT Infrastructure; Intelligent Automation Significantly Reduces OpEx Costs and Dynamically Allocates Resources as Business Needs and Network, Application, or User Conditions Change
SEATTLE, Jun 30, 2009 -- F5 Networks, Inc. (NASDAQ: FFIV), the global leader in Application Delivery Networking (ADN), today announced integration between its BIG-IP(R) solutions and VMware vSphere(TM) 4 and VMware vCenter(TM) Server, together creating a scalable and extensible platform that allows IT administrators to dramatically improve organizations' control over virtual environments. Working in concert, VMware vCenter(TM) Server and F5(R) BIG-IP(R) solutions enable customers to dynamically provision application resources, reduce costs, and maximize the automation and agility of their IT infrastructures.
About F5 Networks
F5 Networks is the global leader in Application Delivery Networking (ADN), focused on ensuring the secure, reliable, and fast delivery of applications. F5's flexible architectural framework enables community-driven innovation that helps organizations enhance IT agility and dynamically deliver services that generate true business value. F5's vision of unified application and data delivery offers customers an unprecedented level of choice in how they deploy ADN solutions. It redefines the management of application, server, storage, and network resources, streamlining application delivery and reducing costs. Global enterprise organizations, service and cloud providers, and Web 2.0 content providers trust F5 to keep their business moving forward. For more information, go to www.f5.com.
-- Jun 26, 2009 Virage Logic Corporation (NASDAQ:VIRL) closed at $4.36 on a volume of 2,036,040 shares.
Virage Logic Sees Strong Adoption of Company's Broad 40nm IP Product Portfolio
More Than 10 Customers Rely on Virage Logic's 40nm G and LP Products to Reduce Design Risk and Speed Time-to-Market
FREMONT, Calif., Jun 30, 2009 -- Virage Logic Corporation (NASDAQ:VIRL), the semiconductor industry's trusted IP partner, today announced that since being named TSMC's 40-namomenter (nm) early development partner in 2007, the company has seen strong adoption of its extensive 40nm product portfolio. Comprising embedded SRAMS, embedded memory test and repair, logic libraries, and memory development software, the Company's silicon-proven 40nm product offering has been designed to optimize area, performance, power and yield. Today, more than ten customers rely on Virage Logic's 40nm product portfolio to design more efficient chips more quickly and with less risk as they develop products for such end markets as graphics, consumer, enterprise, networking, wireless, and handheld.
About Virage Logic
Virage Logic is a leading provider of semiconductor intellectual property (IP) for the design of complex integrated circuits. The company's highly differentiated product portfolio includes embedded SRAMs, embedded NVMs, embedded memory test and repair, logic libraries, memory development software, and interface IP solutions. As the industry's trusted semiconductor IP partner, foundries, IDMs and fabless customers rely on Virage Logic to achieve higher performance, lower power, higher density and optimal yield, as well as shorten time-to-market and time-to-volume. For further information, visit http://www.viragelogic.com.
-- Jun 29, 2009 Vical Incorporated (Nasdaq:VICL) closed at $2.20 on a volume of 1,432,016 shares.
Vical H1 Influenza Vaccine Delivers Robust Preclinical Results With 100% Response
SAN DIEGO, Jun 30, 2009 -- Vical Incorporated (Nasdaq:VICL) announced today that the company's vaccine against A/H1N1 pandemic influenza (swine flu) produced robust immune responses well above the accepted protection threshold in 100% of vaccinated mice and rabbits after a standard two-dose vaccine regimen. In addition, at least 75% of vaccinated animals achieved or exceeded the protection threshold after a single dose of vaccine. The company is ready to advance directly to large-scale cGMP manufacturing of the vaccine for human clinical trials, subject to securing external funding for this program.
About Vical
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com.
About PicksThatMove.com
www.picksthatmove.com team of excellence strives to find undervalued, good momentum stock plays. We provide financial and investor relations services for small to mid-cap stocks with weekly and special newsletters to keep you informed of the latest movers. Unlike other sites, we explore, research, and understand all aspects of a company. We only recommend companies we feel has the potential for future higher valuations. Our seasoned research team is always looking for the next Xtreme Pick to send to you.
www.picksthatmove.com is a leading stock website that provides free daily alerts on stocks that are moving up. www.picksthatmove.com also tracks small cap stocks that are on the brink of exploding. We also feature companies on our website with research report, analysis, and newsletters. To feature a company on our web site please contact us at Info@picksthatmove.com
www.picksthatmove.com is an independent electronic publication that provides information on selected publicly traded companies. www.picksthatmove.com is not a registered investment advisor or broker-dealer. www.picksthatmove.com affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.
CONTACT: PicksThatMove.com
e-mail: Info@picksthatmove.com
WWW: http://www.picksthatmove.com
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
[ Back To CaaS Homepage's Homepage ]
|
CaaS Whitepapers 
